Abstract
Pharmacokinetic studies demonstrated that the decrease in drug biotransformation in hepatic failure depends on the metabolic pathways involved. To test whether glucuronidation reactions supported by UDP-glucuronosyltransferases are differentially affected in such conditions, we investigated the in vitro glucuronidation of four selected drugs and xenobiotics (zidovudine, oxazepam, lamotrigine, and umbelliferone) by using microsomes from human healthy and unhealthy (cirrhosis, hepatitis) livers as enzyme sources. Theses substances are glucuronidated by several UDP-glucuronosyltransferase isoforms. Lidocaine N-deethylation activity measured concomitantly was used as a positive control, because the inhibition of this reaction in patients with hepatic diseases is well documented. The metabolic clearances of zidovudine and lidocaine were decreased significantly in liver cirrhosis (0.17 versus 0.37 μl/min/mg protein and 0.40 versus 2.73 μl/min/mg protein, respectively) as a consequence of a decrease of their corresponding V max of metabolism. By contrast, the metabolic clearances of oxazepam, umbelliferone, and lamotrigine glucuronidation remained unchanged. Previous studies reported that the in vivo oral clearances of zidovudine and lidocaine were decreased by 70% and 60%, respectively, in cirrhotic livers, whereas those of lamotrigine and oxazepam were not affected. Consequently, it is likely that the in vitro metabolic data, which support the in vivo results, therefore could contribute to reasonably predict the level of impairment of hepatic clearance in patients with liver cirrhosis.
Footnotes
-
Send reprint requests to: Anne-Marie Taburet, Clinical Pharmacy, 78, rue du General Leclerc, 94275 Le Kremlin-Bicetre Cedex, France. E-mail:anne-marie.taburet{at}bct.ap-hop-paris.fr
-
↵1 This study was supported, in part, by Glaxo-Wellcome Laboratory (France).
- Abbreviations:
- UGT
- UDP-glucuronosyltransferase
- MEGX
- monoethylglycinexylidide
- UDPGA
- UDP-glucuronic acid
- DMSO
- dimethyl sulfoxide
- Received October 23, 1998.
- Accepted January 12, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|